Therapies
Thursday, July 18th, 2013
JAMA Neurol: 7/1/13 Importance Pooled analysis of randomized controlled trials of intravenous thrombolysis shows no statistically significant benefit beyond 4.5 hours, with the possible advantage perhaps offset by risk. Objective To compare the outcomes of patients who were treated within 4.5 to 6 hours or within 3 to 4.5 hours of the onset of an ischemic […]
News
Thursday, July 18th, 2013
Neurology: July 16, 2013 Objective: We aimed to systematically assess the evidence for differences in the incidence of stroke and distribution of its subtypes in Chinese compared with white populations. Methods: We comprehensively sought studies conducted since 1990 in Chinese populations of 1) first-ever stroke incidence (community-based studies only), and 2) pathologic types/subtypes of stroke (hospital- or community-based […]
News
Thursday, July 18th, 2013
National Institutes of Health: July 16th, 2013 About 60 million Americans take an aspirin a day to reduce the risk of strokes and heart attacks. But for 10 to 30% of those who follow this recommendation, this preventive therapy turns out not to offer any protection. An NIH-funded team, based at Duke University Medical Center, has […]
News
Thursday, July 18th, 2013
STROKEAHA: 7/16/13 The ASCOD Phenotyping Background and Purpose—ASCOD phenotyping (A, atherosclerosis; S, small vessel disease; C, cardiac pathology; O, other causes; and D, dissection) assigns a degree of likelihood to every potential cause (1 for potentially causal, 2 for causality is uncertain, 3 for unlikely causal but disease is present, 0 for absence of […]
News
Thursday, July 18th, 2013
Eur Heart J : 7/16/13 Aims Antihypertensive drug therapy is a major strategy of stroke prevention among hypertensive patients. The aim of this study was to estimate the excess risk of stroke associated with non-adherence to antihypertensive drug therapy among hypertensive patients. Methods and results We conducted a population-based study using records from Finnish national registers for 1 January […]
News
Thursday, July 18th, 2013
Neurology: 7/10/13 Objective: To investigate the relationship between hemorrhagic stroke and use of antiplatelets and warfarin using data from The Health Improvement Network. Methods: A total of 1,797 incident cases of intracerebral hemorrhage (ICH) and 1,340 of subarachnoid hemorrhage (SAH) were ascertained. Density-based sampling was used to select 10,000 controls free from hemorrhagic stroke. Risk of hemorrhagic stroke […]
Atrial Fibrillation
Monday, July 15th, 2013
Wiley: JULY 9, 2013 Atrial fibrillation is associated with poorer outcomes poststroke. It is unclear how the quality of stroke care in hospitals influences outcomes in these patients. Aims The study aims to compare outcomes in stroke patients with and without atrial fibrillation and identify hospital processes of care associated with poor outcomes. Methods Data were […]
Clinical Trials
Monday, July 15th, 2013
FOR IMMEDIATE RELEASE Contact: Gretchen C. Wartman Monday, July 08, 2013 Telephone: 202-223-7560 The National Minority Quality Forum (The Forum) announces that the Pharmaceutical Research and Manufacturers of America (PhRMA) has joined The Forum’s collaboration with Microsoft to launch The National Clinical Trial Network (NCTN). PhRMA represents the country’s leading innovative biopharmaceutical research and […]
Clinical Trials
Monday, July 15th, 2013
Thrombosis Journal: 6/28/2013 Results of clotting tests used to measure the effect of old and new antithrombotic drugs can be expressed in different ways and this is considered as one of the sources of variability to explain the differences of results obtained for the same patient plasma when tested in different laboratories. This is particularly important […]
Clinical Trials
Monday, July 15th, 2013
BMJ: 7/9/13 he AllTrials campaign asks for all trials to be registered and their results published.Ben Goldacre (doi:10.1136/bmj.f1880) says we need the evidence to make informed decisions about medicines. John Castellani says mandatory disclosure could affect patient privacy, stifle discovery, and allow competitors or unscrupulous actors to use the information Clinical trials are essential for the successful development […]
